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FUNCTIONAL GENOMICS OF KRIT1, THE GENE MUTATED IN CEREBRAL 
CAVERNOUS MALFORMATION 
Maxwell S. H. Laurans, Murat Gunel, Richard P. Lifton. Department of Neurosurgery 
and Department of Genetics, Yale University School of Medicine, New Haven, CT. 
Mutations in KRIT1 cause cerebral cavernous malformation, an autosomal 
dominant disease featuring malformation of cerebral capillaries resulting in cerebral 
hemorrhage, strokes and seizures. The biological functions of KRIT1 are unknown. We 
have used specific anti-KRITl antibodies to investigate expression of this protein in 
endothelial cells and human tissues. KRIT1 localizes to the endothelial vasculature of 
diverse human tissues, and to structures important in forming the brain-blood barrier, 
specifically astrocyte foot processes and human cerebral endothelial cells. Within 
endothelial cells, by both microscopy and co-immunoprecipitation, we show that KRIT1 
co-localizes with microtubules during all stages of the cell cycle. In interphase cells, 
KRIT1 is found along the length of microtubules. During mitosis, KRIT1 localizes in a 
pattern indicative of association with microtubule plus ends. These results establish that 
KRIT1 is a microtubule-associated protein; its location at plus ends in mitosis suggests a 
possible role in microtubule targeting. These findings, coupled with evidence of 
interaction of KRIT1 with Krevl and ICAP1 a, suggest that KRIT1 may help determine 
endothelial cell shape and function in response to cell-cell and cell-matrix interactions in 
the CNS by guiding cytoskeletal structure. We propose that the loss of this targeting 
function leads to abnormal endothelial tube formation, thereby explaining the mechanism 
of formation of CCM lesions. 
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INTRODUCTION 
Cerebral Angiogenesis and Vascular Malformations of the Central Nervous System 
This thesis proposes to examine the topic of cerebral angiogenesis by using the 
disease cerebral cavernous malformation (CCM) to develop a framework for 
understanding this process. Four types of vascular malformations exist in the CNS: 
cerebral cavernous malformations (cavernous angiomas), arteriovenous malformations, 
capillary telangiectasias, and venous malformations (1). When affecting the CNS, each 
of these malformations typically occurs in the brain, but has also been identified within 
the spinal cord, particularly in the case of arteriovenous malformations (2). The extent to 
which they might exist outside the vasculature of the central nervous system varies by 
specific malformation and, in the case of cavernous malformations, remains to be 
clarified. Unless otherwise specified, we focus the discussion here on intracranial 
vascular malformations. 
Each type of vascular malformation has a distinct vascular architecture whose 
structure dictates its pathophysiology. In arteriovenous malformation (AVM), the 
capillary bed which normally intervenes between the arterial and venous systems does 
not form. The result is an unusual connection of the high pressure arterial system with 
the low pressure venous system, leading to venous hypertension, steal of normal arterial 
blood flow, and hemorrhage (3). Venous malformations are the least clinically severe 
form of intracranial vascular malformations, and consist of abnormally dilated veins of 
varied thickness and inconsistent intervening smooth muscle components (1). Rarely, 
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these lesions may thrombose and cause neurological deficits (4). Capillary 
telangiectasias, rare vascular malformations in the CNS, manifest as focal dilatations of 
postcapillary venules, often connecting directly with arterioles (5). These lesions more 
commonly exist and cause hemorrhage in mucous membranes and the gastrointestinal 
tract, where they are frequently recognized in their familial form - hereditary 
hemorrhagic telangiectasia (HHT). When cerebral, capillary telangiectasias are often 
associated with cerebral cavernous malformation, a disease of cerebral capillaries which 
fail to form tight junctions (6). In CCM, intravascular contents leak through capillary 
beds allowing for lesion expansion and leading to seizures, headache and neurological 
deficits (7). 
Relatively little is understood with respect to the genetics, molecular biology, and 
pathogenesis of intracranial vascular malformations. Several reports indicate that 
arteriovenous malformations exist within multiple members of a single family, and a 
patient’s risk of developing an AVM increases substantially if a first degree relative is 
diagnosed; however, genetic data does not yet explain this observation (8-14). Though 
not traditionally classified as vascular malformations, intracranial aneurysms also occur 
with increased frequency within families (15-17). These abnormally dilated blood 
vessels occur anywhere in the cardiovascular system, become fragile and susceptible to 
hemorrhage as they expand, and may lead to catastrophic hemorrhage. 
Studies of families suffering the peripheral counterpart to cerebral venous 
malformation (VM) and capillary telangiectasia have identified genes in which germline 
mutations cause these vascular diseases. Activating mutations in TIE2, the receptor for 
angiopoietin-2, result in extracerebral venous malformations; this suggests that the TIE2 
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signaling pathway is important in venous development (18). Mutations in two genes, 
endoglin and activin receptor-like kinase 1 (ALK-1), cause hereditary hemorrhagic 
telangiectasia 1 (HHT1) and HHT2, respectively (19-25). Both are members of the 
transforming growth factor-(3 (TGF-P) receptor family and are expressed predominantly 
on the surface of endothelial cells (26). Endoglin appears to be a necessary component of 
angiogenesis by mouse knockout studies (27). None of these identified mutations have 
been implicated in cerebral vascular malformations. 
Mutations of the gene KRIT1, the subject of this thesis, are now known to be 
responsible for a subset of familial cerebral cavernous malformation cases (28, 29). 
Though the details are largely unclear, it is apparent that each intracranial vascular 
malformation has a genetic component, and it is possible that some of these represent 
perturbations of angiogenic pathways unique to the central nervous system. It is 
intriguing that cavernous malformations, as well as arteriovenous malformations, are 
largely confined to the CNS. However, it remains unclear if the brain and spinal cord are 
merely more sensitive to vascular insufficiency, thereby revealing the lesion, or, 
alternatively, if disturbance of an aspect of angiogenesis expressed only at the vascular- 
CNS interface is responsible. 
Clinical Presentation of Cerebral Cavernous Malformation 
The clinical severity of cavernous malformations varies primarily by lesion 
location, and can range from an incidental finding on magnetic resonance imaging (MRI) 
to rare catastrophic hemorrhage. Presentation more typically occurs in the third to fifth 

4 
decades of life with symptoms of headache, intractable seizures, or focal neurological 
deficits due to stroke. Though female sex appears to correlate with a more clinically 
significant picture, especially during pregnancy, sex does not appear to predispose 
development of cavernous malformation lesions (30). 
CCM has come to be recognized as a common clinical entity with the 
development of MR imaging (31). MR and autopsy studies have identified a prevalence 
of 0.5% for CCM in the United States population, with an estimated 20-30% of these 
affected individuals exhibiting symptomatic disease (7, 32-34). The T1 weighted MR 
appearance of cavernous malformations classically demonstrates asymmetric lesions with 
both hyperintense and hypointense signals (Fig 1). The appearance of blood on MR 
imaging is inconsistent, and may appear hyperintense or hypointense, even within 
hyperacute, acute, subacute and chronic categories (35). The melange of signals which 
are observed in CCM lesions are thought to result from extended periods of chronic, but 
persistent, hemorrhage leading to a deposition of blood products in temporally diverse 
states of degradation. Chronic hemorrhage contributes to and/or is accompanied by 
relatively slow expansion of the lesion. Often, these lesions are described as “popcorn- 
like,” owing to their budding morphology. 
MR appearance of these lesions correlates well with histopathologic findings. 
Microscopic and ultrastructural analysis demonstrates abnormal endothelial cells which 
fail to form the tight junctions typical of the brain-blood barrier (36, 37) (Fig. 2a). The 
cells form leaky channels, or ‘caverns,’ through which blood is thought to hemorrhage, 
instead of the traditional enclosed capillary tube. In addition, lesions lack normal 
intervening structural support such as smooth muscle and mural elements, as well as 
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neural parenchyma (38). Dilated vascular spaces are visualized instead of traditional 
arterioles, capillaries, and venules which become histologically indistinguishable; 
instead, one vascular wall is shared by multiple lumen. In rare cases, cavernous 
malformation lesions have been identified in skin, where they demonstrate similar 
histopathologic features (39) (Fig. 2b). While this histopathology strongly suggests 
abnormal vascular development, an explanation for the focal development of CCM 
remains unclear. 
Treatment for patients suffering cerebral cavernous malformation ranges from 
expectant management to anti-epileptic pharmacotherapy to surgical excision (40). The 
decision to treat is tailored to the individual patient and rests largely on lesion location 
and symptomatology. Surgical treatment is curative in patients with single lesions in the 
absence of an inherited or germline mutation. 

Figure 1: MRI appearance of cerebral cavernous malformation (CCM) 
Axial MRI view of the brain. Characteristic cavernous malformation 
lesion (marked with arrow) is seen within the left temporal lobe. The 
heterogeneous signal within the lesion is indicative of prior hemorrhage. 
Figure 2: (a) Histology of cerebral cavernous malformation lesion (40x). (b) Histology 
of skin cavernous malformation lesion (40x). Both sections are stained with Hematoxalin 
and Eosin and demonstrate similar abnormal vasculature that defines a cavernous 
malformation. Arterioles, capillaries, and venules are indistinguishable, and one 
vascular wall is shared by multiple lumen. 
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The Genetics of Familial Cerebral Cavernous Malformation 
Cerebral Cavernous Malformation is a disease which was long suspected to 
harbor both a sporadic and genetic component. As early as 1936, Michael et al. 
suggested that heritable factors contributed to the development of cavernous angiomas in 
the brain - a disease then believed to be a rare vascular disorder (41). In 1947, Kidd et al. 
described the occurrence of multiple cavernous malformations in a family from Iceland 
(42). Ten to twenty percent of Caucasian patients with CCM have a first degree relative 
with the disease; this proportion increases to 50% among Mexican-Americans 
representing a 20-100 fold increase in risk versus the general population (43), and 
confirming suspicions of a heritable basis for familial cavernous malformation 
pathogenesis. Within families that suffer from CCM, inheritance proceeds through an 
autosomal dominant mechanism (Fig. 3), and patients often harbor multiple cavernous 
malformations (Fig. 4). 
Genome wide linkage analysis in the Mexican-American population initially 
localized one gene, CCM1, to 7q21 (44, 45), establishing that mutation in an unidentified 
gene resulted in cavernous malformation development. Further analysis of Mexican- 
American patients with both a positive family history and apparently sporadic disease 
demonstrated a founder effect among this population and a reduced penetrance for this 
genetic disease (46, 47). Narrowing of the linked interval to a 4 cM region on 
chromosome 7q (48), facilitated positional cloning experiments that proved one of the 
genes located in this region, KRIT1, as the CCM1 gene (28, 29). 
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Figure 3: Representative pedigrees of families with cerebral cavernous malformation 
The CCM inheritance pattern demonstrates vertical and father-son transmission, 
indicating autosomal dominant inheritance. Reduced penetrance is demonstrated by 
the presence of obligate carriers, (circle = female; square = male; grey = unknown status; 
white = unaffected; black = affected; dot = obligate carrier) 
Figure 4: T1 weighted head MR! of multiple cavernous malformation lesions 
in a patient with a positive family history. Some lesions are indicated by arrows. 
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Many groups have now identified myriad mutations in KR1T1 which are causative 
for cerebral cavernous malformation (28, 29, 49-56). Mutational analysis identified the 
founder mutation in the Mexican-American population; a single nucleotide substitution at 
base pair 2105 in exon 14 (2105C->T) predicted premature truncation of the KRIT1 
protein (Q455X) (28, 29). The mutation has not been identified in native populations of 
northern Mexico or Spain (52, 57), and appears to have been the result of a germline 
mutation in a common ancestor subsequent to immigration to the southwestern United 
States. 
To date, 87 mutations have been identified in patients diagnosed with cerebral 
cavernous malformation, and exist throughout the KRIT1 gene (Fig. 5). With one 
exception, sequencing data has demonstrated nonsense, splice site, or frameshift 
mutations in the KRIT1 gene, suggesting a loss of function of the resultant protein. It is 
unclear if this single exception, a missense mutation, is a true mutation or merely a non¬ 
functional polymorphism (53). These data are strongly suggestive of a two-hit 
hypothesis to explain the genetic mechanism behind cavernous malformation 
pathogenesis; however, only examination of CCM tissue will yield such information. 
Analysis of non-Mexican-American kindreds demonstrated linkage for cerebral 
cavernous malformation to two additional loci: CCM2 and CCM3 on 7p 13-15 and 
3q25.2-27 respectively (47). These genes have not yet been identified. 
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KRIT1, the CCM1 Gene 
KRIT1 was incidentally identified in a yeast-two hybrid screen using Krev-1 
(RaplA) as bait (58). The gene was thus named Krev-l/RaplA Interaction Trapped 1. 
Little was known about the function of this protein except that its carboxyl terminus was 
required for interaction with Krev-1 - a highly conserved 21 kDa GTPase-like protein 
with significant homology to the Ras family. Krev-1 has a confirmed interaction with 
Raf, and multiple studies have suggested that it may function as a tumor suppressor gene 
within the Ras signaling pathway (58, 59). 
The KRIT1 gene was initially thought to contain 12 exons which produced a 736 
base pair RNA product resulting in a 63 kDa protein. Subsequent in silico analysis, 
which was later confirmed by experimental data, demonstrated that alternative splicing of 
this gene produced an 81 kDa protein (60, 61). Mutations throughout this larger gene 
have been identified in CCM families (28, 29, 49-57). Interestingly, a subsequent yeast- 
two hybrid study was unable to replicate the interaction between KRIT1 and Krev-1 
when the larger construct is used as bait (62). 
Several motifs have been identified in the KRIT1 sequence (Fig. 6). These 
include a Band 4.1 (FERM) domain, believed to interact with the plasma membrane, 2.5 
ankyrin repeats, and an NPXY domain. 
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Rationale for Investigation of the Molecular Biology of CCM: A Genetic Model for 
Stroke 
Investigation into stroke, a disease affecting 700,000 and killing 200,000 
annually, has been hampered by its multifactorial nature. Roughly 80% of strokes are 
ischemic, the result of thromboembolic disease. The remaining 20% of stroke cases are 
hemorrhagic; significant risk factors include hypertensive episodes, coagulopathic states, 
and cerebrovascular malformations (63). 
The pathogenesis underlying stroke remains obscure. A genetic component of the 
disease is recognized independently of identified risk factors due to twin studies and 
familial aggregation of the disease (64, 65). Additionally, several Mendelian syndromes 
featuring stroke as a prominent component have been identified. These include cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukeoencephalopathy 
(CADASIL) and mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes (MELAS) (66, 67). Identification of mutations in specific genes that lead to the 
stroke phenotype has fueled further investigation into the primary genetic determinants of 
the disease. 
Cerebral cavernous malformation represents another form of Mendelian 
hemorrhagic stroke in which mutation of a single gene - KRIT1, CCM2, or CCM3 - leads 
to an identical phenotype characterized by abnormal intracranial vascular development 
and hemorrhagic stroke. A specific role for KRIT1 in the development or maintenance of 
the CNS vasculature remains unclear; however, it is likely that both the CCM2 and 
CCM3 gene products contribute to this unrecognized system in series or in parallel, given 
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that patients who link to any of these three loci develop lesions which are phenotypically 
indistinguishable. Hence, cerebral cavernous malformation functions as an unusual, 
naturally occurring, model of hemorrhagic stroke; by studying the exception, we seek to 
elucidate the rule. 
Understanding the normal function of KRIT will provide clues to a mechanism 
which explains CCM pathogenesis and the predominant existence of lesions within the 
intracranial vasculature. In rare cases, cavernous malformation lesions in patients with 
known KRIT1 mutations have been identified in the skin and retina, though they do not 
appear to exist independently from cerebral lesions (49, 50, 68). A role for KRIT1 in 
intracranial capillaries is poorly understood and its expression pattern and potential 
function in extracerebral human tissue remains completely uncharacterized. The 
histopathology of cavernous malformation lesions suggests that KRIT1 may be important 
in dictating endothelial cell morphology and in intercellular communication; mutation of 
this protein appears to perturb capillary development in a subset of the endothelial cell 
population. We hypothesize KRIT1 is important in endothelial cell morphogenesis and 
that it specifically affects cerebral capillary development, and cerebral angiogenesis. 
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METHODS 
(Antibody characterization, Western blotting, immunofluorescence microscopy, and RT- 
PCR were performed with the assistance of Dana Shin and Michael DiLuna. 
Immunoprecipitation and immunocytochemistry visualized by confocal microscopy were 
performed solely by the author. Immunohistochemistry visualized by light microscopy 
was performed with the assistance of Ozlem Kayisli.) 
In vitro cell cultures. Bovine Aortic Endothelial Cells (BAE cells) (supplier ATTC, 
Rockville, MD) at early passages (<6) were cultured in high glucose Dulbecco’s 
modified Eagle’s Medium (DMEM) (Gibco BRL, Carlsbad, CA) with 10% Fetal Bovine 
Serum, 100 mM HEPES, 10 mM sodium pyruvate, 100 U ml"1 penicillin G, 100 mg mL"1 
streptomycin, and 0.25 mg ml"1 amphotericin B. COS7 cells were grown in low glucose 
DMEM with 10% fetal bovine serum and 100 U ml"1 penicillin G, 100 mg mL"1 
streptomycin, and 0.25 mg ml"1 amphotericin B. Cells harvested for Western blot and 
RT-PCR analysis were seeded on 100 mm dishes at a concentration of 1 X 107 cells/dish 
and grown to confluence. 
For treatment with the microtubule-depolymerizing drug nocodazole, BAE cells 
were plated on glass slides and cultured. The cells were then treated for 24 hours with 10 
pM of nocodazole and fixed prior to immunocytochemistry. Control cells were cultured 
without nocodazole and fixed and assayed at the same time points. For actin 
depolymerization, BAE cells were incubated with cytochalasin D (Sigma, Saint Louis, 
MO) for 30 minutes prior to fixation. 
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RT-PCR of Bovine Aortic Endothelial cell mRNA. Total cellular RNA was extracted 
from cells grown in tissue culture dishes using Trizol (Gibco BRL, Carlsbad, CA) and 
cDNA was produced via reverse transcription. PCR was performed on cDNA using 
primers specific for KRIT1 (sense - 5’ TACATATGGGCTATAGTGCAC and antisense 
- 5’ TATCAGCTTAGCATCAGGAGCTG), yielding a 1040 bp fragment. Primers for 
GADPH were used to control for RT-PCR efficiency and cDNA synthesis (sense - 5’ 
CCTCTGGAAAGCTGTGGCGT and antisense - 5’ TTGGAGGCCATGTAGGCCAT) 
yielding a 430 bp fragment. 
KRIT1 antibodies. Synthetic peptides corresponding to the following hydrophilic 
segments of KRIT1 were produced: Peptide 1 (KRIT1 259-275), 
DYSKIQIPKQEKWQRS, Peptide 2 (KRIT1 473-490), QLEPYHKPLQHVRDWPE, 
Peptide 3 (KRIT1 724-736, C-terminus), GGGKLNGQLMATERNS. After conjugation 
to KLH, peptides were injected into rabbits and boosted twice; resulting antipeptide 
antibodies were affinity purified using the immunizing peptide (Zymed Laboratories, San 
Francisco, CA). Antibody specificity was tested by Western blotting. 
Characterization of KRIT1 antibodies by Western blot. COS7 cells expressing His- 
tagged KRIT1 (expected size 62 kDa) from a pcDNA4/HisMax/Xpress plasmid 
(Invitrogen, Carlsbad, CA) were lysed and the products fractionated by SDS-PAGE. 
Antibodies were applied to resulting membranes and visualized by chemiluminescence 
(NEN, Boston, MA) (69). 
For protein extraction from endothelial cells, cells were scraped directly into 
boiling sample buffer (100 mM Tris pFI 6.8, 200 mM DTT, 4% SDS, .2% Bromophenol 
Blue, and 20% Glycerol) prior to loading on gels. For SDS-PAGE, protein samples were 
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fractionated by electrophoresis on a 10% acrylamide gel and transferred to membrane. 
Blots were blocked in 10% non-fat dried milk in PBS with 0.05% Tween-20. Blots were 
incubated with primary antibody and staining was detected by incubation with HRP 
donkey-anti-rabbit antibody followed by chemiluminescence. For peptide competition 
assays, primary antibody was competed by a 4-fold molar excess of the immunizing 
peptide prior to incubation. 
Tissue collection and preparation. Human adult tissues were obtained from the 
Department of Pathology, Yale University School of Medicine (protocol # 7680). 
Informed consent was obtained and protocols were approved by the Human Investigation 
Committee. Each tissue was divided into three sections for analysis by RT-PCR, 
Western blot, and immunohistochemistry. Protein extraction was carried out 
immediately following tissue collection using T-PER tissue protein extraction reagent 
(Pierce, Rockford, IL) supplemented with a protease inhibitor cocktail, as was RNA 
extraction using Trizol reagent (Gibco BRL, Carlsbad, CA); tissue to be used for 
immunohistochemical analysis was fixed overnight in 4% paraformaldehyde, embedded 
in paraffin, cut to a thickness of 5-7 pm, and mounted on gelatin-coated slides. 
Semi-quantitatvie analysis of KRIT1 transcription by PCR. A cDNA library 
(Clontech, Palo Alto, CA) was used to assess KRIT1 transcription in human fetal tissues. 
PCR was performed using primers specific for KRIT1 (sense - 5’ 
ACTGGGAAGAAGCTGCAAAA and antisense - 5’ CTGTGAAAAATGCTGCTCCA), 
yielding a 717 base pair fragment. Primers for actin were used to control for RT-PCR 
efficiency and cDNA synthesis (sense - 5’ TTGCTGATCCACATCTGCTG and 
antisense - 5’ GACAGGATGCAGAAGGAGAT) yielding a 120 base pair fragment. 
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Resulting signal was quantified by a digital imaging and analysis system (AlphaEase, 
Alpha Innoteh Corporation San Leandro Ca) where the intensity of each KRIT1 band was 
normalized to its corresponding actin band such that semi-quantitative comparison could 
be made between samples. 
Semi-quantitative analysis of KRIT1 expression by Western blot. Protein 
concentration was determined by a detergent compatible protein assay (Pierce). For 
SDS-PAGE, 20 pg protein samples were fractionated by electrophoresis on a 7.5% Tris- 
HC1 acrylamide gel and transferred to nitrocellulose membrane. Blots were blocked in 
5% non-fat dried milk in PBS with 0.05% Tween-20, incubated with primary antibody 
followed by HRP donkey anti-rabbit secondary antibody, and visualized by 
chemiluminescence (69), or HRP mouse anti-human GADPH antibody (Santa Cruz 
Biotecnology, Santa Cruz, CA). Membranes were subsequently stripped and reprobed 
with HRP mouse-anti-human GADPH antibody to confirm that equal amounts of protein 
was loaded. Bands visualized on Western blot were quantified using a laser densitometer 
(AlphaEase, Alpha Innoteh Corporation San Leandro Ca), and KRIT1 signal was 
normalized to signal generated by GADPH. 
Immunohistochemistry. Tissue sections were de-paraffmized and re-hydrated in an 
alcohol gradient prior to analysis by a standard streptavidin-biotin technique. 
Endogenous peroxidase activity was blocked by incubation in 3% H2O2 (0.6 ml of H202 
and 2.7ml of methanol and 2.7 ml of d H20). Slides were blocked with 5% normal goat 
serum, incubated overnight with human polyclonal rabbit anti-KRITl antibody at 4 °C, 
and incubated for 30 min at 25 °C with secondary biotinylated goat anti-rabbit IgG 
(Vector Laboratories, Inc., Burlingame, CA). Slides were incubated with the 
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streptavidin-peroxidase complex using the Vectastain ABC Elite kit (Vector 
Laboratories). Chromogenic reactions were completed with 3-amino 9-ethyl carbazole 
(AEC) to yield a positive red stain, or 3, 3'-diaminobenzidine (DAB) to yield a positive 
brown stain (Vector Laboratories, Inc.). Slides were counterstained with haematoxylin 
prior to mounting and visualization by light microscopy. All immunostaining with anti- 
KRIT1 antibody was competed with a two-fold molar excess of the immunizing peptide. 
Subsequent incubation with secondary antibody and evaluation as above yielded no 
signal. 
Intensity of staining by KRIT1 antibodies was semi-quantitatively evaluated. 
Two investigators, acting independently, scored five 40x high power fields (HPFs) for 
percentage of positively stained cells within the following categories: - (no staining) 1 + 
(weak but detectable), 2+ (moderate or distinct), 3+ (intense). For each cell type or tissue 
section, an HSCORE value was derived according to the following formula: 
HSCORE= P, (i+1) 
where i represents the intensity scores and P, is the corresponding percentage of the cells. 
Immunoprecipitation. For immunoprecipitation, adherent Bovine Aortic Endothelial 
Cells (BAE cells) were grown to confluency and lysed in ice-cold cytoskeletal lysis 
buffer (0.5% NP-40, 10 mM Pipes pH 6.8, 50 mM NaCl, 300 mM sucrose, 3 mM MgCl2) 
with protease inhibitors (4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatinA, 
E-64, bestatin, leupeptin, and aprotinin) (Sigma, Saint Louis, MO). The lysate was 
precleared with Protein G Plus-Agarose (Oncogene, La Jolla, CA), after which p-tubulin 
antibody (developed by Michael Klymkowsky, obtained from the Developmental Studies 
Hybridoma Bank developed under the auspices of the NICHD and maintained by The 
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University of Iowa, Department of Biological Sciences, Iowa City, IA 52242) or KRIT1 
antibody, separately coupled to Protein G Plus Agarose, was used for 
immunoprecipitation. After overnight incubation at 4 °C, beads were collected by 
centrifugation, washed with lysis buffer, boiled and fractionated by SDS-PAGE gel 
electrophoresis and analyzed by Western blotting as described above. 
Imrnunocytochemistry. Cells were split onto microscope slides and grown for 24 hours. 
The slides were washed with PBS, fixed with 3% paraformaldehyde, and permeabilized 
in 0.2% Triton-xlOO in PBS. The sections were blocked with 10% normal donkey serum 
(NDS) and 1% BSA in PBS. They were incubated with primary followed by secondary 
antibody, stained with DAPI and mounted. (3- and a-tubulin primary antibodies were 
purchased from Sigma. For actin staining, cells were incubated with 1 pM Phalloidin 
(Sigma, Saint Louis, MO) conjugated to rhodamine. For cold induced fracture of 
microtubules, BAE cells were incubated in ice cold PBS for varying amounts of time and 
allowed to recover at 37 °C, followed by imrnunocytochemistry. 
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RESULTS 
Antibody characterization 
Antibodies to KRIT1 peptides were produced and affinity purified. Resulting antibodies 
were tested for specificity by Western blotting and immunohistochemistry. Antibodies 
directed against the 13 amino acid peptide at the C-terminus of the protein specifically 
stained a peptide of the expected size in extracts of COS7 cells transfected with a his- 
tagged KRIT1 construct (Fig. 7a). This staining is competed with the immunizing 
peptide (Fig. 7b) demonstrating its specificity. 
KRIT1 is expressed in endothelial cell lines 
The antibody also identified a product of the expected size for endogenous KRIT1 in 
untransfected bovine aortic endothelial (BAE) cells (Fig. 8a). RT-PCR analysis 
confirmed the presence of KRIT1 mRNA (Fig. 8b) in BAE cells, and the sequence of this 
product identified it as the KRIT1 ortholog (86% nucleotide and 85% amino acid 
sequence identity to human KRIT1). 
Relative expression of KRIT1 in human tissue 
Expression of KRIT1 in human tissue was evaluated by examining extracted protein on 
Western blot and probing with KRIT1. KRIT1 is expressed strongly in human kidney, 
liver, and lung, moderately in pancreas and spleen, and weakly in brain (Fig. 9). 
Expression in fetal tissue was examined by using a human fetal cDNA library, and 
demonstrated a similar pattern of distribution (Fig. 10). 
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Figure 7: Characterization of specific anti-KRITl antibodies 
Anti-KRITl antibodies were used to stain Western blots of extracts of COS7 
cells. These cells, which do not express endogenous KRIT1, were 
transfected either with plasmid expressing his-tagged KRIT1 (+) or an empty 
vector (-) as described in methods, (a) Staining detected a protein of size 
expected for the fusion protein in cells transfected with KR1T1. (b) Peptide 
competition eliminates staining, demonstrating the specificity of this antibody 
for the KRIT1 protein. 
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Figure 8: (a) Western blot of native BAECs using anti-KRITl. A 58 kDa 
band is detected when protein isolated from BAEC cultures is probed with 
anti-KRITl antibodies; this band is competed by the immunizing peptide. 
(b) RT-PCR reveals KRIT1 mRNA expression in BAECs. The sequence of the 
product reveals an encoded protein of 85% identity with human KRIT1. 
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Figure 9: KRIT1 is expresed in 
diverse human tissues 
Expression of KRIT1 protein in 
human tissue was evaluated by 
Western blot probed by antibodies 
specific for KRIT1. Equal amounts 
of protein were loaded in each lane, 
and blots were probed for KRIT1, 
stripped and then probed for GADPH. 
Band signal was quantified, and 
normalized to housekeeping protein 
GADPH such that meaningful 
comparisons could be made between 
tissue types. The protein is expressed 
strongly in kidney, liver, and lung, 
moderately in pancreas and spleen, 
and weakly in brain. 
Figure 10: Relative expression of 
KRIT1 in human fetus 
Quantitative RT-PCR was performed using 
a cDNA library to assess for KRIT1 
transcription level. RNA was quantified 
subsequent to reverse transcription, and 
resulting signal intensity was normalized 
to that of aetin in each respective sample. 
KRIT1 is most strongly expressed in liver, 
and moderately expressed in lung, kidney, 
spleen and thymus. 
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Immunolocalization of KRIT1 
Localization of KRIT1 within adult human tissue was determined by 
immunohistochemical staining of paraffin embedded tissue which was visualized by light 
microscopy after streptavidin-biotin exposure. 
KRIT1 stains endothelial cell cytoplasm in human brain tissue, the cell in which 
we hypothesized the disease phenotype would primarily manifest (Fig. 11a). Semi- 
quantitative analysis of staining in the cerebrovasculature indicates that endothelial cells 
of capillary beds and arterioles stain more intensely than venous counterparts (Fig. lib). 
In larger, more complex vascular structures, the tunica intima stains most intensely, 
followed by the foot processes of astrocytes which abut the tunica adventitia. The 
smooth muscle of the tunica media does not react with antibodies directed to KRIT1. 
In the cortex of brain parenchyma, anti-KRITl antibodies positively stain the 
cytoplasm of select neuronal cell bodies in cortex layers 1-6, with cortex layer 5, the 
internal pyramidal layer, exhibiting the most intense staining (Figs. 12 & 13). In 
particular, the cytoplasm of select pyramidal cells of both the internal and external 
pyramidal layers (cortex layers 3 and 5) react with antibodies directed to KRIT1. Other 
cells in the granular layers do not stain for KRIT1. 

Figure 11a: KRIT1 expression in human cerebrovasculature 
Specific antibodies directed to KRIT1 were incubated in slides of paraffin embedded 
human adult brain. The resulting streptavidin-biotin reaction reveals a brown signal 
to indicate a positive stain, (a) Endothelial cells of the cerebral vein (V) stain weakly 
for KRIT1 (arrow), while those of the corresponding artery (Art) stain more strongly 
(arrowhead). Foot processes of astrocytes abutting the tunica adventitia (A) stain 
positively for KRIT1 (double arrowhead), (b) Endothelial cells of the artery stain 
positively for KRIT1 along with astrocytic foot processes. The cytoplasm of additional 
astrocytes also stain positively for KRIT1 (double arrow), (c) Endothelial cells of 
cerebral capillaries (c) react with antibodies directed to KR1T1, as do endothelial cells 
of arterioles (a). 
(V = vein; Art = artery; A = tunica adventitia; M = tunica media; I = tunica intima; 
arrow = weakly/absent staining endothelial cells; arrowhead = intensely staining 
endothelial cells; double arrowhead = astrocytic foot processes; 
double arrow = astrocyte; a = arteriole; c = capillary) 
Figure lib: Semi-quantitative analysis of KRIT1 
expression by cerebral cell type 
Degree of staining for KRIT1 protein was assessed 
semi-quantitatively and categorized by cell type. 
Cells of capillary bed endothelium and arterioles 
stain more strongly than venous counterparts. 
Endothelium 
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Figure 12: Immunolocalization ofKRITl in the cerebral cortex 
Paraffin embedded sections of human cerebral cortex were stained with anti-KRITI 
antibodies (brown). KRIT1 protein is present in pyramidal neurons which arc most 
most commonly located in cortex layers 3 and 5. the internal and external pyramidal 
layers, (arrow = positively staining cell) 
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Figure 13: KRIT1 stains pyramidal cells in the cerebral cortex 
In this section from the internal pyramidal layer, cortex layer 5, KRIT1 antibodies 
intensely stain pyramidal neurons (red). (Arrowhead = positively staining cell) 
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KRIT1 is present in vascular structures of varied organs in the human body. In 
each organ, KRIT1 is primarily expressed by small vessels including capillary beds and 
arterioles, and rarely expressed by larger vascular structures. KRIT1 stains the 
endothelium most strikingly in organs with an extensive vascular supply such as liver and 
spleen (Fig. 14). In the heart and in skeletal muscle, markedly intense staining for KRIT1 
is observed in arteries, while expression in veins is absent (Fig. 14a & 14b). In skin, 
endothelial cells of arterioles and capillaries stain for KRIT1 in the dermis; this is most 
striking among the small vessels which comprise the sub-papillary plexus. Epithelial 
cells of sweat glands, the ducts of these glands and hair follicles also express KRIT1. 
The epidermis, which lacks significant vascular supply, does not express KRIT1 except 
in the stratum basale. This cuboidal layer of cells lies at the junction between the dermis 
and epidermis, is joined to the basement membrane by hemi-desmosomes, and stains 
weakly for KRIT1 (Fig 14c). In the liver, KRIT1 staining is absent in the portal vein but 
present in arteriolar branches of the hepatic artery that run through the portal tract; the 
protein is not expressed by the fenestrated capillaries of hepatic sinusoids in the liver 
parenchyma (Fig. 14d). Numerous small branches of the inferior thyroid and internal 
thoracic arteries enter the thymus at the interlobular septa that is continuous with the 
collagenous capsule surrounding the lymphoid organ. KRIT1 distinctly stains the 
endothelial cells of these branches, but not their corresponding venous counterparts (Fig. 
14e). 

Figure 14: KRIT1 localization in vascular endothelium of heart, skeletal muscle, skin, 
liver, and thymus 
Paraffin embedded sections of human tissue were stained with anti-KRITI antibody (brown). 
(a) In heart arterial endothelium, antibodies to KRIT1 yield an intense positive signal (arrowhead) 
while the corresponding vein lacks signal altogether (arrow), (b) Arterial endothelium of skeletal 
muscle stains positively for KRIT1 while the corresponding vein does not react with antibodies to 
K.RIT1. (c) Endothelial cells of arterioles and capillaries in the sub-papillary plexus of the dermis 
(SPP) stain positively for KRIT1, as do epithelial cells of sweat glands (SG), sweat ducts (SD), 
and hair follicles (HF). Weak staining is observed in the stratum basale (SB, double arrowhead), 
(d) The thin endothelial cells of the portal vein (PV) fail to react with anti-KRITI antibodies while 
arteriolar branches of the hepatic artery stain for the protein (arrowhead), (e) Branches of the 
inferior thyroid and internal thoracic artery stain positively for KRIT1 where they enter the thymus 
at the interlobular septa (IS) while corresponding venules do not. (arrow = endothelial cell without 
staining for KRIT1; arrowhead = endothelial cell positively staining for KRIT1; SB, double 
arrowhead = stratum basale; SPP = sub-papillary plexus; SG = sweat gland; SD = sweat duct; 
HF = hair follicle; double arrow = hepatic sinusoid; PV = portal vein; IS = interlobular septa) 
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This data establishes the presence of KRIT1 in human endothelial cells, but fails 
to characterize the specific function of this protein. We hypothesize that subcellular 
KRIT1 influences endothelial cell morphogenesis and that its mutation prohibits normal 
microvascular development. 
KRIT1 is associated with microtubules 
We localized KRIT1 in BAE cells by immunocytochemistry. During interphase, we 
observed that KRIT1 localized to the cytoplasm with a pattern suggesting association 
with a component of the cytoskeleton (Fig. 15). To further characterize this pattern, we 
used double and triple staining with antibodies directed against KRIT1 and either actin, 
or tubulin (Fig. 16). KRIT1 showed co-localization with tubulin, but not with actin. 
Confocal microscopy confirmed the same pattern of co-localization with KRIT1 showing 
a granular staining pattern along the length of microtubules (Fig. 17). 
This association of KRIT1 with tubulin was further explored by treatment of BAE 
cell cultures with nocodazole, which depolymerizes microtubules (70). Following 
nocodazole treatment, both tubulin and KRIT1 staining showed characteristic 
cytoplasmic “clumps” instead of the typical spindle pattern (Fig. 18). Disruption of 
microtubules with cold also confirmed KRITEs association with microtubules (Fig. 19). 
The continued co-localization with tubulin demonstrates the association of KRIT1 and 
tubulin in both polymerized and depolymerized states (Figs. 18 & 19) suggesting that 
KRIT1 is a microtubule-associated protein. 
Actin depolymerization with cytochalasin D did not have any effect on KRIT1 
staining or its association with microtubules (data not shown). 

Figure 15: Immunocytochemistry of KRIT1 expression in BAE cells 
KRIT1 staining localizes to the cytoplasm of BAE cells in a pattern suggesting 
an association with the cytoskeleton. (green = KRIT1; red = actin; blue = dapi) 
KRIT1 ^-Tubulin Actin Composite 
Figure 16: KRIT1 co-localizes with beta-tubulin 
BAE cells were stained with antibodies to KRIT1, actin and beta-tubulin. 
KRIT1 staining reveals a filamentous pattern that differs from actin 
staining but overlaps with that of beta-tubulin; magnification 63X. 

KRIT1 (3-Tubulin Composite 
Figure 17: Confocal microscopy of BAE cell stained for beta-tubulin and KRIT1 
Confocal image demonstrates co-localization of KRITI with beta-tubulin in a 
granular pattern along the length of microtubules; magnification 63X. KRITI 
staining was competed by the immunizing peptide (data not shown). 
Figure 18: Immunocytochemistry of nocodazole treated BAE cells 
Cultured endothelial cells were treated with nocodazole. Following 
treatment, KRITI staining changes to a pattern of cytoplasmic granules. 
KRITI continues to co-localize with beta-tubulin, (magnification 63x) 
(Composite image: green = KRITI, red = beta-tubulin, blue = DAPI) 

Figure 19: Co-localization of KRIT1 and beta-tubulin following cold treatment 
Following indicated treatments of cultured BAECs, cells were stained for KR1T1 
and beta-tubulin. Following 5 minutes (a) or 20 minutes (b) on ice, disruption of 
microtubules is observed, affecting both beta-tubulin and KR1T1 staining. 
Following 20 minutes of recovery at 37 °C, microtubules have repolymerized and 
KRIT1 staining is seen along their length (c). 
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KRIT1 interacts with tubulin 
In order to determine whether KRIT1 and (3-tubulin can be found together in a physical 
complex in vivo, co-immunoprecipitation experiments were performed. Either KRIT1 or 
(3-tubulin antibody was used for immunoprecipitation from BAE cell lysates; the 
precipitated protein was evaluated by Western blotting using these same antibodies. 
Complexes immunoprecipitated with P-tubulin antibodies contain KRIT1 (Fig. 20a). 
Conversely, complexes immunoprecipitated with antibodies to KRIT1 contain P-tubulin 
(Fig. 20b). In contrast, control antibodies directed against proteins not believed to form a 
complex with either KRIT1 or P-tubulin are not found in these complexes (Fig. 20). 
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Figure 20: Co-immunoprecipitation of K.RITI and beta-tubulin 
BAE cell lysates were immunoprecipitated with mouse anti-Bax (lane 1), or mouse 
anti-beta-tubulin (lane 2). Lane 3 has been loaded with an equal amount of beta-tubulin 
antibody as lane 2 but without cell lysate. Western blots were prepared and probed with 
rabbit anti-KRITl antibody. The results demonstrate a band the size of KRIT1 only 
when lysate is precipitated with anti-beta-tubulin, (b) BAE cell lysates were immunoprecipitated 
with rabbit anti-Bax in lane I and rabbit anti-KRITl in lane 2. An equal amount of K.RIT1 
antibody has been loaded in lane 3. Western blots were prepared and probed with mouse 
antibody to beta-tubulin. The results demonstrate a band the size of beta-tubulin only when 
the lysate is precipitated with KR1T1. 
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Distribution of KRIT1 during endothelial cell mitosis 
To further explore the association of KRIT1 with microtubules, we investigated 
endothelial cells throughout mitosis. During metaphase, KRIT1 staining was most 
intense at the spindle pole bodies and the plus ends of the astral microtubules at the 
kinetochore of the mitotic spindle, paralleling the location of (3-tubulin (Figs. 21 & 22). 
Similarly, during anaphase A, when chromosomes are separated by shrinking of 
kinetochore fibers, the region of the overlapping plus ends of the interpolar microtubules 
of the interzone showed strong KRIT1 staining (Figs. 21 & 22), again consistent with 
plus end association. Finally, the staining pattern was particularly striking in late 
telophase during which KRIT1 localization is prominent at the midbody remnant, the site 
of cytokinesis where the extreme plus ends of microtubules of the two dividing cells 
overlap (Figs. 21 & 22). At these locations, KRIT1 staining can be seen to extend 
beyond the tip of (3-tubulin expression (Fig. 22). This is consistent with KRITFs 
location at the extreme plus end of microtubules. 

Figure 21: Mitotic BAE cells stained for KRIT1 and alpha-tubulin 
Cultured endothelial cells were stained with antibodies to K.RIT1 (green, (a)), 
DAPI (blue), and antibodies to alpha-tubulin (red, (b)). During prometaphase and 
metaphase, antibodies to KRIT1 intensely stain the spindle pole bodies and 
the mitotic spindle. As cells progress through anaphase and into telophase, 
KRIT1 staining is most striking in the central portion of the midbody. In late 
telophase KRIT1 localizes to the midbody remnant, consistent with the presence 
of KRIT1 at microtubule plus ends. 

Figure 22: Mitotic BAE cells stained for K.RIT1 and beta-tubulin 
Cultured endothelial cells were stained with antibodies to KRIT1 (green (a)), 
DAPI (blue), and antibodies to beta-tubulin (red, (b)). During Pr°metaphase 
and metaphase, antibodies to KRIT1 intensely stain the spindle pole bodies 
and the mitotic spindle. As cells progress through anaphase and into te ophase, 
KRIT1 staining is most striking in the central portion of the midbody In late 
telophase KRIT 1 localizes to the midbody remnant, extending beyond beta-tubu in 
staining, consistent with the presence of KRIT1 at microtubule plus ends. 
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DISCUSSION 
Despite the existence of KRIT1 in most human organs, the protein is not 
uniformly distributed, but instead specifically localizes to extracerebral and cerebral 
vascular endothelium, astrocytes, and pyramidal cells of the cerebral cortex. In a diverse 
array of tissues, antibodies to KRIT1 predominantly detect the protein in endothelial cells 
of capillaries and arterioles. 
In the cerebral vasculature, KRIT1 is expressed by normal endothelial cells of 
capillaries, arterioles, and weakly by larger arteries. In addition, antibodies to this protein 
positively stain foot processes (endfeet) of astrocytes which abut the tunica adventitia of 
larger vessels on both the arterial and venous side of the circulation. The significance of 
this localization of KRIT1 is unclear; however, both of these structures - the endothelium 
and astrocytic endfeet - are important in the formation and maintenance of the brain- 
blood barrier. It is intriguing that in fenestrated capillaries of liver sinusoids, capillaries 
which lack tight junctions and whose endothelial cells fail to adhere to one another, 
KRIT1 is not expressed, and that cavernous malformation lesions predominantly develop 
in the unique environment established in the cerebral microvasculature. 
The brain-blood barrier functions to protect the brain from fluctuations in plasma 
composition and from circulating agents which might disturb neural function. In 
addition, it assists in homeostatic regulation of the brain microenvironment necessary for 
normal function of the CNS (71). Cerebral capillaries are joined by a complex set of 
tight junctions (zonula occludens), which prevent transportation of hydrophilic 
substances to the brain parenchyma. Necessary polar substances, such as glucose, are 
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transported through specific carriers, such as GLUT-1 (72). This vascular-parenchymal 
interface is unique to the CNS, though a number of these properties are found to a lesser 
degree in peripheral capillary endothelium. Astrocytes and their foot processes, cells in 
which KRIT1 is expressed, contribute to the upregulation of endothelial tightening and 
downregulation of permeability factors which establishes and maintains the blood brain 
barrier (73-75). 
Together these results confirm the presence of KRIT1 in the cerebral endothelial 
vasculature, and reveal that the protein is broadly, but specifically expressed by vascular 
endothelium in diverse human tissues. The presence of KRIT1 in extracerebral organs 
raises a central question: why are cavernous malformation lesions predominantly 
observed in the brain? Ultrastructural analysis of cavernous malformation lesions 
demonstrates an absence of tight junctions and astrocytic foot processes, indicating a role 
for blood-brain barrier breakdown in cerebral cavernous malformation pathophysiology 
(36). This data suggests that KRIT1 may participate in the development of the blood- 
brain barrier phenotype by assisting in focal adhesion of endothelial cells, or 
communication with astrocytes, or both. It is intriguing that the only other tissues in 
which cavernous malformation lesions are known to develop - the skin and retina -also 
contain elements of primitive neuroectoderm. An explanation for the focal nature of 
cavernous malformation lesions remains unclear, but perturbations of the blood brain 
barrier in cavernous malformation lesions and localization of the causative protein to 
these structures strongly suggests a specific role for KRIT 1 in cerebral microvascular 
development. 
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These studies, in the context of known disease pathology, suggest that KRIT1 
influences endothelial cells. Further studies, aimed at understanding this influence at the 
subcellular level, have identified an interaction between microtubules - highly dynamic 
structures important in determining cellular morphology - and KRIT1. The targeting and 
attachment of these polar structures appears to be directed by microtubule-associated 
proteins (MAPs). Microtubules are nucleated at minus ends originating at the 
centrosome/microtubule-organizing center; these minus ends are enriched in a-tubulin. 
Growth and shrinkage occurs at microtubule plus ends, which are enriched in (3-tubulin; 
these plus ends explore the intracellular space and can be guided toward specialized 
membrane domains and chromosomes by specific plus-end-tracking proteins (76). We 
have shown that KRIT1 is a microtubule-associated protein that demonstrates increased 
localization to microtubule plus ends during mitosis. Immunoprecipitation experiments 
confirm that KRIT1 and (3-tubulin are present within the same complexes, though they do 
not necessarily indicate a direct interaction. 
The finding that KRIT1 can be located at microtubule plus ends suggests a 
potential role in targeting of microtubules, and the phenotype resulting from loss of 
KRIT1 function suggests a possible model for development of CCM lesions. One of the 
first stages of angiogenesis involves tube formation by endothelial cells; this 
tubulogenesis is triggered by interactions of endothelial cells with one another and with 
the extracellular matrix. Intercellular adhesion via PECAM1 (platelet endothelial cell 
adhesion molecule-1) provides signaling essential for endothelial tube formation (77, 78). 
It is intriguing that the GTPase activity of Krevl, an interacting partner of KRIT1 (58, 62, 
79), is specifically activated by this interaction. This suggests a potential signaling 
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pathway connecting cell-cell contact via PECAM1 to the microtubule cytoskeleton via 
Krevl and KRIT1. Such a connection involving Krevl and the cytoskeleton has been 
made in yeast, in which the sole homologue of Krevl is Budl/RSRl, which is required 
for normal selection of the budding site, a process which involves targeting of 
microtubules (80). Similarly, ICAP1 a, the other known KRIT1- interacting protein, is 
known to bind to the cytoplasmic C-terminus of |31-integrin, thereby communicating 
information about cell-matrix interaction to the cell interior. Consequently, the link 
between KRIT1 and microtubules, on the one hand, and KRIT1 with Krevl and ICAP1 a 
on the other provides a potential pathway for signals from cell-cell contact and cell- 
matrix interaction, respectively, to influence cytoskeletal structure (Fig. 23). The loss of 
this function could lead to the abnormal capillary development seen in patients with 
CCM due to impaired microtubule targeting, resulting in impaired tubulogenesis. 
This proposed function of KRIT1 in targeting microtubules in response to 
external signals is reminiscent of that of EB1, another plus end microtubule-binding 
protein. EB1 binds to the tumor suppressor APC, and it has been proposed that the 
activity of the Wnt signaling pathway is involved in the regulation of this interaction and 
the consequent targeting of microtubules (81). 
These findings together provide the first localization of KRIT1 and also provide a 
framework for understanding the mechanism by which loss of KRIT1 causes human 
disease. Further work will be required to establish a role for KRIT1 in microtubule 
targeting and in determining the specific roles of other molecules involved in this 
pathway. 

Integrin 
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CD3l-dependant cell adhesion 
Figure 23: Proposed function for K.RIT1 in the endothelial cell 
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CONCLUSIONS 
This thesis has attempted to characterize the function of the cerebral cavernous 
malformation 1 protein, KRIT1, as a means to understanding hemorrhagic stroke and 
neurovascular development. Data uncovered here and elsewhere strongly suggest that 
KRIT1, a protein which is expressed in vascular endothelium of various organs, functions 
in communication between endothelial cell microtubules and the (3-integrins, and is 
stimulated by and/or responds to cell-cell interactions. It is intriguing that when 
overexpressed, ICAP1 a disrupts focal adhesions in endothelial cells, perhaps simulating 
the cavernous malformation phenotype (82). It remains unclear to what degree KRIT1 
participates in regulating ICAP1 a function and the development of focal adhesions, 
though both KRIT1 and the cytoplasmic pi integrin tail compete for the same binding 
site on this protein (62, 79). Additionally, although KRIT1 is present in nearly all 
capillary beds, it fails to stain endothelial cells that lack tight junctions - hepatic 
sinusoids. 
These discoveries have proceeded in a stepwise fashion in pursuit of examining 
the KRIT1 protein for the purpose of understanding cavernous malformation 
pathogenesis and cerebrovascular development. Given the disease phenotype, it seems 
likely that KRIT1 serves a unique purpose in the CNS. Further investigations will be 
aimed at further revealing this role, identifying CCM2 and CCM3, and contextualizing 
these primary genetic determinants of stroke. 
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